Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD40 | P25942 | 1/20 | 0.84 |
| ▸ | CD40LG | P29965 | 1/20 | 0.84 |
| ▸ | ENPP2 | Q13822 | 12/20 | 0.66 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.56 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.56 |
| ▸ | EP300 | Q09472 | 1/20 | 0.56 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19958353 | 0.91 | CD40 (1.00) | CD40CD40LGENPP2PRMT1PRMT3 | |
| SCHEMBL12931503 | 0.87 | CD40 (0.78) | CD40CD40LGENPP2PRMT1PRMT3 | |
| SCHEMBL14025107 | 0.82 | CD40 (0.81) | CD40CD40LGENPP2PRMT1PRMT3 | |
| SCHEMBL19882740 | 0.81 | CD40 (0.79) | CD40CD40LGENPP2PRMT1PRMT3 | |
| SCHEMBL13703533 | 0.80 | CD40 (0.78) | CD40CD40LGENPP2PRMT1PRMT3 | |
| SCHEMBL17277636 | 0.80 | CD40 (0.74) | CD40CD40LGENPP2PRMT1PRMT3 | |
| SCHEMBL13138837 | 0.79 | CD40 (0.73) | CD40CD40LGENPP2PRMT1PRMT3 | |
| SCHEMBL14370961 | 0.79 | CD40 (0.69) | CD40CD40LGENPP2PRMT1PRMT3 | |
| SCHEMBL30661045 | 0.78 | ENPP2 (0.96) | CD40CD40LGENPP2PRMT1PRMT3 | |
| SCHEMBL29538633 | 0.78 | ENPP2 (0.86) | CD40CD40LGENPP2PRMT1PRMT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070972-A1 | MODULATORS | XOMA US LLC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12371488-B2 | Modulators | XOMA (US) LLC (US) | 2025-07-29 | — | — | US | disclosed |
| US-11975049-B2 | Therapeutic treatment for neurotrophic keratopathy | Struck, Michael (US) | 2024-05-07 | — | — | US | disclosed |
| US-20220227857-A1 | NOVEL MODULATORS | XOMA (US) LLC | 2022-07-21 | — | — | US | disclosed |
| US-11261247-B2 | Modulators | XOMA (US) LLC (US) | 2022-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070972-A1 | MODULATORS | INSR, IGF1R, IRS1 | CD40 427/4885CD40LG 462/4885ENPP2 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.